Anti-TNFalpha polyclonal antibody - Verigen
Alternative Names: PASSTNF-alphaLatest Information Update: 19 Sep 2000
At a glance
- Originator Verigen AG
- Developer Italchimici; Verigen Europe A/S
- Class
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 19 Sep 2000 No-Development-Reported for Crohn's disease in Italy (Unknown route)
- 19 Sep 2000 No-Development-Reported for Rheumatoid arthritis in Denmark (Unknown route)
- 19 Sep 2000 No-Development-Reported for Rheumatoid arthritis in Italy (Unknown route)